title: Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis.
abstract: We report a new case of therapy-related acute myeloid leukemia in a child with Langerhans cell histiocytosis. This patient was previously treated with a protocol of multidrug chemotherapy, containing a relatively low dose of etoposide (total dose of 900/m(2)). Twenty-six months after the end of the therapy, the patient returned to the hospital with fever and anemia. The white blood cell count was 53 x 10(9)/L. The bone marrow examination showed massive infiltration with French-American-British acute myeloid leukemia classification M4 blast cells. The patient did not respond to an intensive treatment with high dose ARA-C and idarubicin. He died 6 months later. The cytogenetic abnormality of the blast cells was a t(11;11)(p13 -15;q23), that has not been described before in a secondary leukemia case.
authors.affiliation: Laboratorio de Citogenetica, Centro de transplante de Medula Ossea (CEMO), Instituto Nacional de Cancer (INCA), Rio de Janeiro, Brazil. luizamacedo@hotmail.com
authors.forename: Maria Luiza Macedo
authors.initials: ML
authors.lastname: Silva
authors.forename: Marcelo Gerardin Poirot
authors.initials: MG
authors.lastname: Land
authors.forename: Simone
authors.initials: S
authors.lastname: Maradei
authors.forename: Luize
authors.initials: L
authors.lastname: Otero
authors.forename: Melissa
authors.initials: M
authors.lastname: Veith
authors.forename: Gilena
authors.initials: G
authors.lastname: Brito
authors.forename: Claudete
authors.initials: C
authors.lastname: Klumb
authors.forename: Teresa
authors.initials: T
authors.lastname: Fernandez
authors.forename: Maria Socorro
authors.initials: MS
authors.lastname: Pombo-de-Oliveira
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002675:Child, Preschool; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D003561:Cytarabine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D017809:Fatal Outcome; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007621:Karyotyping; D015479:Leukemia, Myelomonocytic, Acute / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000235:genetics*; D028861:Nuclear Pore Complex Proteins / Q000235:genetics; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D004791:Enzyme Inhibitors; D028861:Nuclear Pore Complex Proteins; D059005:Topoisomerase II Inhibitors; C093350:nuclear pore complex protein 98; D003561:Cytarabine; D014747:Vinblastine; D005047:Etoposide; D011239:Prednisolone; D015255:Idarubicin